Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Fagan

Pulmonary Disease Columbus, OH Medical Doctor

NPI 1073599387 CMS profile 275275

745 W State St, Ste 510, Columbus, OH 43222

Open in the dashboard

General payments

$178,911

186 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Fagan of Columbus, OH is reported in the CMS Open Payments database as having received $178,911 across 186 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $53,290 54
2024 General $56,432 60
2023 General $16,502 14
2022 General $22,331 20
2021 General $16,547 21
2020 General $5,305 7
2019 General $8,506 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Fagan
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to James Fagan were reported at $53,290. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year James Fagan Pulmonary Disease median Middle half National median
2019 $8,506 $377 $109–$1,340 $163
2020 $5,305 $230 $56–$907 $114
2021 $16,547 $269 $68–$1,072 $132
2022 $22,331 $390 $100–$1,457 $149
2023 $16,502 $419 $114–$1,659 $160
2024 $56,432 $476 $123–$1,818 $164
2025 $53,290 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $178,911 186 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $165,380 66 payments
  2. Travel and Lodging $8,308 62 payments
  3. Food and Beverage $5,223 58 payments
Products named General payments · program years 2019–2025
  1. BREZTRI $165,001 163 payments
  2. BREZTRI AEROSPHERE $5,305 7 payments
  3. DALIRESP $4,997 4 payments
  4. SYMBICORT $2,015 3 payments
  5. BEVESPI AEROSPHERE $1,494 3 payments
  6. AIRSUPRA $44 3 payments
  7. FARXIGA $29 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

186 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record